Umibecestat Alzheimer Disease Prevention Trials Discontinued
Two pivotal phase 2/3 studies investigating umibecestat (CNP520) for the prevention of Alzheimer disease have been discontinued due to worsening in some measures of cognitive function.
Neurocognitive Disorders
Estradiol May Protect Against Cognitive Impairment Mediated by Visceral Adiposity
Estradiol has anti-inflammatory properties and can strengthen the hypothalamic-pituitary-adrenal axis, which may oppose the effects of visceral adiposity.
Nilvadipine Increases Hippocampal Cerebral Blood Flow in Alzheimer Disease
Blood pressure reduction with nilvadipine resulted in an increase in hippocampal cerebral blood flow while global flow remained stable.
Anesthesia Linked to Neurocognitive Impairment in Childhood ALL Survivors
Multiple exposures to general anesthesia may be associated with neurocognitive impairment and brain imaging abnormalities in long-term survivors of childhood acute lymphoblastic leukemia.
Family History of Dementia Tied to Early Memory Deficits
A first-degree family history of dementia is associated with memory deficits decades before the typical onset of Alzheimer disease.
Cognitive Decline Accelerates After Incident Coronary Heart Disease
Accelerated cognitive decline is associated with incident coronary heart disease after, but not before or immediately following, ischemic events.
Incident A-Fib Linked to Increased Dementia Risk
Incident atrial fibrillation (AF) is associated with increased dementia risk in elderly populations.
Dementia Tied to Anticholinergic Use
In a prospective study, the odds of dementia increased nearly 50% with daily use of anticholinergics for 3 years at the minimum effective dose recommended for older adults.
Seniors Who Develop Cancer Have Better Memory, Slower Decline
Researchers compared long-term memory trajectories in patients before and after they developed incident cancer to those of similarly aged individuals not diagnosed with cancer.
Alzheimer Disease Markers Predict Subsequent Decline in Mild Cognitive Impairment
Age and Alzheimer disease biomarkers are associated with decline in patients with mild cognitive impairment who initially reverted to normal cognition.
Next post in Neurocognitive Disorders
